Autonomix Medical, Inc. (NASDAQ: AMIX) (“Autonomix” or the “Company”), a medical device company dedicated to advancing precision nerve-targeted treatments, today announced its long-term data titled ...
Groundbreaking interim results from U.S. REGAIN trial in recurrent glioblastoma demonstrate 100% local disease control, 67% complete response ...
NImmune Biopharma ("NImmune"), a private, late-stage precision inflammation and immunology ("I&I") biopharmaceutical company, presented two studies at Digestive Disease Week (DDW), which together ...
Even as colorectal cancer screening rates have risen among older adults across race and ethnicity, racial disparities in ...
Epirium Bio Inc. (Epirium), a clinical-stage biopharmaceutical company advancing medicines for neuromuscular, inflammatory, and fibrotic diseases, is presenting new translational data on its oral ...
Washington (May 14, 2024) — Cancer-related studies, including a diagnostic tool for gastric cancer and trends in gallbladder and colorectal cancers, will be presented this week at Digestive Disease ...
New data presented at Digestive Disease Week 2026 reinforces endoscopic remission as being associated with long-term patient ...
Single-Fiber Digital Pathology Quantification Reveals Multidimensional Fibrosis Architecture in Eosinophilic Esophagitis Beyond Collagen Area Ratio These results underscore the value of PharmaNest's ...
HealthDay on MSN
Digestive Disease Week, May 2-5
Digestive Disease Week (DDW), the annual meeting sponsored by the American Association for the Study of Liver Diseases, ...
Palisade Bio's PALI-2108 will be presented at Digestive Disease Week 2025, highlighting its potential in ulcerative colitis treatment. Palisade Bio's lead program PALI-2108 has been recognized, being ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results